Literature DB >> 17090686

Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer.

Babak Oskouian1, Prathap Sooriyakumaran, Alexander D Borowsky, Angelina Crans, Lisa Dillard-Telm, Yuen Yee Tam, Padmavathi Bandhuvula, Julie D Saba.   

Abstract

Sphingolipid metabolites such as sphingosine-1-phosphate (S1P) and ceramide modulate apoptosis during development and in response to stress. In general, ceramide promotes apoptosis, whereas S1P stimulates cell proliferation and protects against apoptosis. S1P is irreversibly degraded by the enzyme S1P lyase (SPL). In this study, we show a crucial role for SPL in mediating cellular responses to stress. SPL expression in HEK293 cells potentiated apoptosis in response to stressful stimuli including DNA damage. This effect seemed to be independent of ceramide generation but required SPL enzymatic activity and the actions of p38 MAP kinase, p53, p53-inducible death domain protein (PIDD), and caspase-2 as shown by molecular and chemical inhibition of each of these targets. Further, SPL expression led to constitutive activation of p38. Endogenous SPL expression was induced by DNA damage in WT cells, whereas SPL knockdown diminished apoptotic responses. Importantly, SPL expression was significantly down-regulated in human colon cancer tissues in comparison with normal adjacent tissues, as determined by quantitative real-time PCR (Q-PCR) and immunohistochemical analysis. Down-regulation of S1P phosphatases was also observed, suggesting that colon cancer cells manifest a block in S1P catabolism. In addition, SPL expression and activity were down-regulated in adenomatous lesions of the Min mouse model of intestinal tumorigenesis. Taken together, these results indicate that endogenous SPL may play a physiological role in stress-induced apoptosis and provide an example of altered SPL expression in a human tumor. Our findings suggest that genetic or epigenetic changes affecting intestinal S1P metabolism may correlate with and potentially contribute to carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090686      PMCID: PMC1859938          DOI: 10.1073/pnas.0600050103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients.

Authors:  Susan R Schwab; João P Pereira; Mehrdad Matloubian; Ying Xu; Yong Huang; Jason G Cyster
Journal:  Science       Date:  2005-09-09       Impact factor: 47.728

2.  Regulation of sphingosine-1-phosphate lyase gene expression by members of the GATA family of transcription factors.

Authors:  Babak Oskouian; Jane Mendel; Ellyn Shocron; Michael A Lee; Henrik Fyrst; Julie D Saba
Journal:  J Biol Chem       Date:  2005-02-25       Impact factor: 5.157

Review 3.  Activation and signaling of the p38 MAP kinase pathway.

Authors:  Tyler Zarubin; Jiahuai Han
Journal:  Cell Res       Date:  2005-01       Impact factor: 25.617

4.  The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity.

Authors:  Padmavathi Bandhuvula; Yuen Yee Tam; Babak Oskouian; Julie D Saba
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

5.  A novel caspase-2 complex containing TRAF2 and RIP1.

Authors:  Mohamed Lamkanfi; Kathleen D'hondt; Lieselotte Vande Walle; Marjan van Gurp; Geertrui Denecker; Jill Demeulemeester; Michael Kalai; Wim Declercq; Xavier Saelens; Peter Vandenabeele
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

Review 6.  Anticancer compounds and sphingolipid metabolism in the colon.

Authors:  Rui-Dong Duan
Journal:  In Vivo       Date:  2005 Jan-Feb       Impact factor: 2.155

7.  Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner.

Authors:  Junxia Min; Paul P Van Veldhoven; Lei Zhang; Marie H Hanigan; Hannah Alexander; Stephen Alexander
Journal:  Mol Cancer Res       Date:  2005-05       Impact factor: 5.852

8.  Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium.

Authors:  Guochun Li; Hannah Alexander; Natalie Schneider; Stephen Alexander
Journal:  Microbiology (Reading)       Date:  2000-09       Impact factor: 2.777

9.  p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury.

Authors:  Rohit Seth; Cheng Yang; Varsha Kaushal; Sudhir V Shah; Gur P Kaushal
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

10.  High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.

Authors:  Yukihiro Akao; Yoshiko Banno; Yoshihito Nakagawa; Nobuko Hasegawa; Tack-Joong Kim; Takashi Murate; Yasuyuki Igarashi; Yoshinori Nozawa
Journal:  Biochem Biophys Res Commun       Date:  2006-02-21       Impact factor: 3.575

View more
  112 in total

1.  Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.

Authors:  Perry C Kennedy; Ran Zhu; Tao Huang; Jose L Tomsig; Thomas P Mathews; Marion David; Olivier Peyruchaud; Timothy L Macdonald; Kevin R Lynch
Journal:  J Pharmacol Exp Ther       Date:  2011-06-01       Impact factor: 4.030

2.  Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and viral cytopathogenicity.

Authors:  Young-Jin Seo; Celeste Blake; Stephen Alexander; Bumsuk Hahm
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

3.  Sphingosine kinase localization in the control of sphingolipid metabolism.

Authors:  Deanna L Siow; Charles D Anderson; Evgeny V Berdyshev; Anastasia Skobeleva; Viswanathan Natarajan; Stuart M Pitson; Binks W Wattenberg
Journal:  Adv Enzyme Regul       Date:  2010-11-12

Review 4.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

5.  A facile stable-isotope dilution method for determination of sphingosine phosphate lyase activity.

Authors:  Jung H Suh; Abeer Eltanawy; Apoorva Rangan; Julie D Saba
Journal:  Chem Phys Lipids       Date:  2015-09-25       Impact factor: 3.329

Review 6.  Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

Authors:  S-K Jo; A Bajwa; A S Awad; K R Lynch; M D Okusa
Journal:  Kidney Int       Date:  2008-03-05       Impact factor: 10.612

Review 7.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

Review 8.  PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism.

Authors:  Florence Bourquin; Guido Capitani; Markus Gerhard Grütter
Journal:  Protein Sci       Date:  2011-09       Impact factor: 6.725

Review 9.  Metabolic Regulation of Apoptosis in Cancer.

Authors:  K Matsuura; K Canfield; W Feng; M Kurokawa
Journal:  Int Rev Cell Mol Biol       Date:  2016-07-30       Impact factor: 6.813

10.  Pharmacogenetics of resistance to Cisplatin and other anticancer drugs and the role of sphingolipid metabolism.

Authors:  Stephen Alexander; William S Swatson; Hannah Alexander
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.